新京报贝壳财经讯 6月25日,佰金生命科学公告,由于附属公司管理层变更后的交接过程较预期耗时更长,且公司于本周初方全面控制附属公司的运营,故截至2025年3月31日止年度之年度业绩将延迟刊发。核数师及公司需要更多时间以编制2025年度业绩。预计2025年度业绩将于2025年7月25日前刊发。根据上市规则第13.5条,若发行人未能根据上市规则之规定刊发定期财务资料,联交所通常会要求暂停买卖发行人之...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.